Table 2.
Summary of randomized, controlled clinical trials with GLP-1 RAs in T1DM
| Study | Number of patient | Study duration, weeks | Mean duration of diabetes, years | Treatment groups | Change in A1c (%) | Change in insulin dose | Change in body weight (kg) |
|---|---|---|---|---|---|---|---|
| Kielgast et al,46 2011 | 39 | 4 | 3.7 17.3 23.1 |
C-peptide pos + liraglutide 1.2 mg daily C-peptide neg + liraglutide 1.2 mg daily C-peptide neg + insulin alone |
−0.26 −0.47 −0.18 |
−0.194 units/kg −0.13 units/kg +0.017 units/kg |
−2.3 −2.3 +0.2 |
| Frandsen et al,48 2015 | 40 | 12 | 18.3 19.5 |
Liraglutide 1.2 mg daily Placebo |
−0.6 −0.5 |
NR | −3.1 +1.1 |
| Kuhadiya et al,47 2016 | 72 | 12 | 30 25 21 20 |
Placebo Liraglutide 0.6 mg daily Liraglutide 1.2 mg daily Liraglutide 1.8 mg daily |
−0.3 −0.26 −0.78 −0.42 |
−1.9 units −2.8 units −12.1 units −10.0 units |
0 −3.0 −5.0 −5.0 |
| Dejgaard et al,52 2016 | 100 | 24 | 20 25 |
Liraglutide 1.8 mg daily Placebo |
−0.5 −0.3 |
+4.1 units +13.4 units |
−5.9 +0.2 |
| Mathieu et al,49 2016 | 1398 | 52 | 20.9 21.6 21.5 21.6 |
Liraglutide 0.6 mg daily Liraglutide 1.2 mg daily Liraglutide 1.8 mg daily Placebo |
−0.43 −0.49 −0.54 −0.34 |
+4% −2% −5% +4% |
−1.3 −2.7 −4.0 +0.9 |
| Ahren et al,50 2016 | 835 | 26 | 21 21.1 21.4 20.7 |
Liraglutide 0.6 mg daily Liraglutide 1.2 mg daily Liraglutide 1.8 mg daily Placebo |
−0.24 −0.23 −0.35 +0.01 |
NR NR NR NR |
−2.5 −4.0 −5.1 −0.2 |
Abbreviations: A1c, hemoglobin A1c; GLP-1 RAs, glucagon-like peptide-1 receptor agonists; neg, negative; NR, not reported; pos, positive; T1DM, type 1 diabetes mellitus.